The CKD patients with hypertension
Conditions
Interventions
Daily administration of irbesartan 100mg with trichrolmethiazide 0.5-1mg
Administration of irbesartan 100mg daily with tricholmethiazide 1-2mg every other day
Sponsors
Department of Internal Medcine, Teikyo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Chronic kidney disease 2) Patients without acute changes in renal function and with stability in general condition 3) Hypertensive patients during treatment with antihypertensive drugs, or hypertensive patients whose blood pressures have not achieved to the targeted level recommended by "CKD guideline 2012" 4) Patients over the age of 20, unquestioned gender 5) The patients who we can obtain the informed consent signed by themselves.
Exclusion criteria
Exclusion criteria: 1) The patient with contraindication of irbesartan medication 1. Patients with a history of hypersensitivity to any component of this drug 2. Patients during pregnancy and with pregnant possibility 2) The patient with contraindication of the trichrolmethiazide medication 1. Patients with anuria 2. Patients with acute renal failure 3. Patients with hyponatremia, and hypokalemia 4. Patients with a history of hypersensitivity to thiazides or analogues 3) Patients who are judged ineligible for any other reasons by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change of blood pressure (office blood pressure, home blood pressure) 2. Changes of serum uric acid level | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in renal function (serum creatinine, eGFR, serum cystatin C et al.) 2. Changes in urinary examinations (urine protein et al.) 3. Changes of metabolic biomarkers (lipids, glucose and electrolytes) 4. Changes of heart rate | — |
Countries
Japan
Contacts
Public ContactShunya Uchida
Teikyo University School of Medicine Department of Internal Medcine
Outcome results
None listed